loader
Please Wait
Applying Filters...

Digital Content for Sapanisertib

Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20240717288408/en

BUSINESSWIRE
17 Jul 2024

https://www.globenewswire.com/news-release/2022/10/03/2526655/0/en/Calithera-Receives-FDA-Fast-Track-Designation-for-Sapanisertib-for-the-Treatment-of-NRF2-mutated-Squamous-Lung-Cancer.html

GLOBENEWSWIRE
03 Oct 2022

https://www.globenewswire.com/news-release/2022/08/15/2498526/32478/en/Calithera-Biosciences-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Highlights.html

GLOBENEWSWIRE
15 Aug 2022

https://www.globenewswire.com/news-release/2022/07/13/2479319/32478/en/Calithera-Biosciences-Shares-Progress-in-Sapanisertib-and-Mivavotinib-Clinical-Programs-at-Upcoming-Lung-Cancer-and-Lymphoma-Conferences.html

GLOBENEWSWIRE
13 Jul 2022

https://www.globenewswire.com/news-release/2022/07/06/2475432/32478/en/Calithera-Biosciences-Announces-First-Patient-Enrolled-in-Phase-2-Clinical-Trial-of-Sapanisertib-in-Relapsed-Refractory-NRF2-NFE2L2-Mutated-Squamous-Non-Small-Cell-Lung-Cancer.html

GLOBENEWSWIRE
06 Jul 2022

https://www.thepharmaletter.com/article/two-new-drugs-add-harmony-to-calithera-s-precision-pipeline?__cf_chl_jschl_tk__=pmd_x66vxwinkDHJdlA02hF8AvCwosLXtWK1gLCV4NmksrM-1634712524-0-gqNtZGzNApCjcnBszQs9

THEPHARMALETTER
20 Oct 2021